Global Sepsis Diagnostics Market to Witness 7% CAGR, Driven by POC & Biomarker Adoption 2030

The global sepsis diagnostics market is set to witness a growth rate of ~7% in the next 5 years. High incidence of sepsis cases globally, increasing use of biomarker and molecular tools, government initiatives & sepsis awareness, and rising demand for POC testing, are some of the key factors driving the sepsis diagnostics market. 

Sepsis diagnostics are tests or processes used to diagnose sepsis, a potentially lethal condition resulting from the body's extreme response to infection. Sepsis diagnostics help in detecting infection, characterizing the level of dysfunction to the organ systems, and guide timely treatment. Blood cultures, molecular diagnostic tests (like Polymerase Chain Reaction - PCR), biomarkers (e.g., procalcitonin, C-reactive protein), and point-of-care tests are some of the approaches to sepsis diagnostics. Rapid and accurate diagnostics in this process is crucial, and delay in diagnostics often lead to increased morbidity and mortality. Sepsis diagnostics benefit emergency departments, intensive care units, and laboratories by improving clinical outcomes and reducing costs to the overall healthcare system. 

🔗 Want deeper insights? Download the sample report:
https://meditechinsights.com/sepsis-diagnostics-market/request-sample/

High incidence of sepsis cases globally to drive market growth

A significant factor contributing to the growth of sepsis diagnostics market is the high incidence of sepsis cases. Sepsis is one of the leading causes of death globally and in 2020 there were 48.9 million cases and 11 million deaths resulting from sepsis, representing approximately 20% of all deaths worldwide (Source: WHO). The high prevalence is linked to aging population, chronic disease, the emergence of antimicrobial resistance, and hospital-acquired infections. Since sepsis can rapidly progress to organ failure, early identification and accurate diagnosis are paramount. Increased incidence has added to the need for enhanced modes of diagnosis like molecular diagnostics, biomarker assays, and rapid point-of-care tests. Consequently, governments and providers are creating protocols for early detection and treatment of sepsis, investing in diagnostic technology, and increasing access across the continuum of hospital and critical care.

Favorable initiatives & funding for sepsis research

Sepsis remains a poorly understood condition due to limited diagnostic tools and few specific treatments. In an endeavor to shape the future of sepsis research, The National Institute of General Medical Sciences (NIGMS) has set its priorities to invest in sepsis research in a more targeted and strategic way. NIGMS intends to use the NIH SBIR/STTR program to support preclinical and clinical sepsis studies to develop improved diagnostic tools and therapies. To prevent millions of deaths each year from sepsis, diagnostics companies are also continuously securing funding to develop rapid sepsis diagnostic tests

Emphasis on hospital-acquired infection (HAI) detection – A key market trend  

A significant aspect of sepsis diagnostics is related to the increased emphasis on HAI detection, as HAIs are a common source of sepsis within critical care settings. The increase in ICU admissions and invasive procedures over the years has made early HAI detection crucial to prevent sepsis related complications and deaths. Hospitals are increasingly incorporating rapid diagnostic tools to monitor blood stream infections and antimicrobial resistance among others. In addition, stricter infection control regulations, reimbursement policies, and efforts to reduce hospital stay durations and associated healthcare costs are some of the other factors fueling this trend.

Development of rapid diagnostic tests/point-of-care techniques set to drive the sepsis diagnostics market

Sepsis is a potentially life-threatening condition and early and accurate diagnosis is critical for survival. Currently, clinicians possess limited technology needed to conduct multiplexed and fully quantitative diagnostic tests at the point of care with high sensitivity. Citing the need for rapid diagnostic tests, several research universities and product manufacturers are developing innovative rapid diagnostic tests/point-of-care techniques.

 “With sepsis, timing is the key. Advancements in diagnostic speed, range, and accuracy are critical for addressing the continued rise in sepsis cases and deaths. Advent of new rapid diagnostic tests for sepsis can save thousands of lives.”

- Senior Director, Leading In-Vitro Diagnostics Manufacturer, United States

Competitive Landscape Analysis

The global sepsis diagnostics market is marked by the presence of established and emerging market players such as Biomérieux; Becton, Dickinson & Company (BD); Danaher Corporation; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Bruker; Abbott Laboratories; Siemens Healthineers; Qiagen; and DiaSorin S.p.A.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

 Gain a competitive edge-request a sample report now! 
https://meditechinsights.com/sepsis-diagnostics-market/request-sample/

Global Sepsis Diagnostics Market Segmentation

This report by Medi-Tech Insights provides the size of the global sepsis diagnostics market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, technology, pathogen type, diagnostic method, test type, and end user.

Market Size & Forecast (2023-2030), By Product, USD Million

• Instruments
• Reagents & Assays
• Blood Culture Media
• Software & Platforms

Market Size & Forecast (2023-2030), By Technology, USD Million

• Microbiology Testing
• Molecular Diagnostics
• Immunoassays
• Flow Cytometry
• Microfluidics
• Others

Market Size & Forecast (2023-2030), By Pathogen Type, USD Million

• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis
• Others

Market Size & Forecast (2023-2030), By Diagnostic Method, USD Million

• Conventional Diagnostics
• Automated Diagnostics

Market Size & Forecast (2023-2030), By Test Type, USD Million

• Laboratory Testing
• Point-of-Care Testing

Market Size & Forecast (2023-2030), By End User, USD Million

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
• US
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Rest of Asia Pacific
• Latin America
• Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com